This may, in part, explain the trend in benefit observed in the patients with GCB DLBCL, which is consistent with the improvement in outcome seen in patients with FL when treated with G-CHOP versus R-CHOP [14]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.